Tumour necrosis factor inhibitor-induced myositis in a patient with ulcerative colitis

Modern Rheumatology Case Reports ◽

10.1080/24725625.2020.1800958 ◽

2020 ◽

Vol 5 (1) ◽

pp. 156-161

Author(s):

Akitsu Yoshida ◽

Yasuhiro Katsumata ◽

Shinya Hirahara ◽

Masanori Hanaoka ◽

Moeko Ochiai ◽

...

Keyword(s):

Ulcerative Colitis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Inhibitor ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

Sa1753 - Tofacitinib Achieves Symptomatic Improvement within 3 Days in Moderately to Severely Active Ulcerative Colitis, Regardless of Prior Tumour Necrosis Factor Inhibitor Treatment Status: Results from Octave Induction 1 & 2

Gastroenterology ◽

10.1016/s0016-5085(18)31577-4 ◽

2018 ◽

Vol 154 (6) ◽

pp. S-381-S-382

Author(s):

Stephen B. Hanauer ◽

Remo Panaccione ◽

Silvio Danese ◽

Adam S. Cheifetz ◽

Walter Reinisch ◽

...

Keyword(s):

Ulcerative Colitis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Symptomatic Improvement ◽

Tumour Necrosis Factor Inhibitor ◽

Active Ulcerative Colitis ◽

Treatment Status ◽

Factor Inhibitor ◽

Necrosis Factor ◽

Inhibitor Treatment

Download Full-text

DOP024 Tofacitinib achieves symptomatic improvement within 3 days in moderately to severely active ulcerative colitis, regardless of prior tumour necrosis factor inhibitor treatment status: results from OCTAVE induction 1 and 2

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjx180.061 ◽

2018 ◽

Vol 12 (supplement_1) ◽

pp. S046-S048 ◽

Author(s):

S Hanauer ◽

R Panaccione ◽

S Danese ◽

A Cheifetz ◽

W Reinisch ◽

...

Keyword(s):

Ulcerative Colitis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Symptomatic Improvement ◽

Tumour Necrosis Factor Inhibitor ◽

Active Ulcerative Colitis ◽

Treatment Status ◽

Factor Inhibitor ◽

Necrosis Factor ◽

Inhibitor Treatment

Download Full-text

Faculty Opinions recommendation of Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1108991.565450 ◽

2008 ◽

Author(s):

Martin Aringer ◽

Alexander Kleymann

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Joint Damage ◽

Tumour Necrosis Factor Inhibitor ◽

Inadequate Response ◽

Structural Joint ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

OP0201 A phase 3 study of the efficacy and safety of ixekizumab in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitor(s)

10.1136/annrheumdis-2017-eular.1576 ◽

2017 ◽

Author(s):

P Nash ◽

B Kirkham ◽

M Okada ◽

P Rahman ◽

B Combe ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Inhibitor ◽

Inadequate Response ◽

Efficacy And Safety ◽

Phase 3 ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

AB0446 Physician-reported behaviours and treatment trends of tumour necrosis factor inhibitor use: cycling versus switching in five european countries: france, germany, italy, spain and the uk

10.1136/annrheumdis-2018-eular.2991 ◽

2018 ◽

Author(s):

J.R. Curtis ◽

E. Sullivan ◽

J. Kershaw ◽

S. Blackburn ◽

P. Mahajan ◽

...

Keyword(s):

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Inhibitor ◽

European Countries ◽

Factor Inhibitor ◽

The Uk ◽

Treatment Trends ◽

Necrosis Factor

Download Full-text

FRI0098 Elevated multi-biomarker disease activity (MBDA) predicts relapses in ra patients in sustained remission tapering tumour necrosis factor inhibitor therapy- results from the randomized controlled retro study

10.1136/annrheumdis-2017-eular.4787 ◽

2017 ◽

Author(s):

J Rech ◽

M Hagen ◽

M Englbrecht ◽

J Haschka ◽

M Reiser ◽

...

Keyword(s):

Disease Activity ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Inhibitor ◽

Inhibitor Therapy ◽

Sustained Remission ◽

Randomized Controlled ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

Management with secukinumab of tumour necrosis factor inhibitor‐induced pulmonary sarcoidosis‐like reaction in a patient with psoriasis

Clinical and Experimental Dermatology ◽

10.1111/ced.14101 ◽

2019 ◽

Vol 45 (4) ◽

pp. 455-456 ◽

Author(s):

G. Eichhoff

Keyword(s):

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Pulmonary Sarcoidosis ◽

Tumour Necrosis Factor Inhibitor ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort

Rheumatology ◽

10.1093/rheumatology/kex457 ◽

2017 ◽

Vol 57 (4) ◽

pp. 619-624 ◽

Author(s):

Fariz Yahya ◽

Karl Gaffney ◽

Louise Hamilton ◽

Ellie Lonsdale ◽

Jane Leeder ◽

...

Keyword(s):

United Kingdom ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Axial Spondyloarthritis ◽

Tumour Necrosis Factor Inhibitor ◽

Predictors Of Response ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

Tumour necrosis factor inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients

Annals of the Rheumatic Diseases ◽

10.1136/ard.2002.004226 ◽

2004 ◽

Vol 63 (3) ◽

pp. 318-320 ◽

Author(s):

C Pritchard

Keyword(s):

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Inhibitor ◽

Factor Inhibitor ◽

Necrosis Factor ◽

Inhibitor Treatment

Download Full-text

248 Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis

Rheumatology ◽

10.1093/rheumatology/key075.472 ◽

2018 ◽

Vol 57 (suppl_3) ◽

Author(s):

Jonathan Massey ◽

Darren Plant ◽

Kimme Hyrich ◽

Ann W Morgan ◽

Anthony G Wilson ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Association Study ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Genome Wide Association Study ◽

Tumour Necrosis Factor Inhibitor ◽

Genome Wide Association ◽

Genome Wide ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text